Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAG | P20916 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HRAS | P01112 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967108 | 1.00 | MAG (0.50) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL5841546 | 0.91 | MAG (0.55) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL5841001 | 0.91 | MAG (0.55) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL5841006 | 0.91 | MAG (0.55) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL22204678 | 0.91 | MAG (0.55) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL10905974 | 0.90 | SSTR4 (0.46) | MAGL3MBTL1POLBSSTR1SSTR2 | |
| SCHEMBL10905976 | 0.90 | SSTR4 (0.46) | MAGL3MBTL1POLBSSTR1SSTR2 | |
| SCHEMBL7233754 | 0.88 | L3MBTL1 (0.44) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL8822949 | 0.87 | SSTR4 (0.47) | L3MBTL1POLBSSTR1SSTR2SSTR4 | |
| SCHEMBL11293173 | 0.86 | MAG (0.45) | MAGSLC6A2HRASPOLBLGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653049-B2 | Normuramyl glycopeptide compounds | IMUTHES LIMITED (GB) | 2014-02-18 | — | — | US | disclosed |
| EP-2578598-A1 | Componds derived from normuramyldipeptide | IMUTHES LIMITED (GB) | 2013-04-10 | — | — | EP | disclosed |
| EP-2271661-A2 | COMPOUNDS DERIVED FROM MURAMYLDIPEPTIDE | IMUTHES LIMITED (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20110002983-A1 | COMPOUND | IMUTHES LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| WO-2009115782-A2 | COMPOUND | IMUTHES LIMITED (GB) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002983-A1 | COMPOUND | C5AR1, C5AR2, ARG1 | MAG 394/4885LGALS8 754/4885SLC6A2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.